This study highlights novel genotype-driven metabolic adaptations in PM, laying the groundwork for targeted interventions ...

Two Indian nationals were sentenced to 30 months in prison for smuggling counterfeit cancer drugs into the US.

Merck & Co. said Wednesday it will acquire London-based Verona Pharma in a $10 billion all-cash deal, bolstering its respiratory treatment portfolio as the company moves to reduce long-term dependence ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

The Different Types of Mesothelioma There are three main types you need to know about - pleural, peritoneal, and pericardial. First is pleural, the leading type, attacking the lining of your lungs ...

Diagnosed with an asbestos-related disease? Our expert team is here to help. Recognised as leading mesothelioma and asbestos solicitors, we secure rightful compensation for those affected. Contact us ...

CNBC's Angelica Peebles reports on themes emerging in the pharma space. Donald Trump announces deal to end Republican revolt Kathy Bates’ Emmys nod says a lot about the state of TV Nurse who ...

While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Read why MRK is a Buy.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

FDA takes major step to ease access to CAR-T therapy The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ post-treatment movement.

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.